ReviewAnnals of medicine2026
Breaking barriers in peritoneal fibrosis: extracellular vesicles as promising diagnostic and therapeutic strategy.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal dialysis is an essential therapy for end-stage kidney disease, but its long-term efficacy is severely limited by peritoneal fibrosis. Driven by mesothelial-mesenchymal transition, inflammation and angiogenesis, this pathological process leads to treatment failure and increased mortality. The urgent need for effective therapies has shifted research focus to extracellular vesicles-phospholipid bilayer nanovesicles that shuttle bioactive cargoes to modulate pathogenic pathways, positioning them as key mediators in peritoneal fibrosis. DISCUSSION: This review synthesises preclinical evidence to evaluate the dual diagnostic and therapeutic potential of extracellular vesicles. By analysing their cellular sources and regulatory roles in fibrotic pathways, we highlight their promise as both non-invasive biomarkers and targeted therapeutic agents for peritoneal fibrosis. It further integrates these mechanistic insights with critical translational hurdles, including unstandardised technical preparation, unclear
conclusionExtracellular vesicles hold great potential as novel non-invasive biomarkers and targeted therapeutic agents for peritoneal fibrosis. This review outlines a developmental roadmap for extracellular vesicles-based strategies by combining mechanistic findings with translational challenges. Addressing these critical gaps will be pivotal to unlocking the clinical value of extracellular vesicles, preserving peritoneal membrane function and improving long-term outcomes for relevant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.